Enanta Pharmaceuticals Announces Data Presentations at AASLD’s The Liver Meeting® 2021
October 01 2021 - 7:00AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage
biotechnology company dedicated to creating small molecule drugs
for viral infections and liver diseases, today announced that the
company will have two poster presentations showcasing clinical data
for EDP-514, a novel pangenotypic class II hepatitis B virus (HBV)
core inhibitor, at The Liver Meeting® 2021, hosted by the American
Association for the Study of Liver Diseases (AASLD), being held
November 12 – November 15, 2021. EDP-514 is being developed for use
in combination treatments for patients with chronic HBV (CHB).
The meeting platform with posters will open on November 8, 2021
at 8:00 a.m. Enanta will have two poster presentations:
Poster Title: “EDP-514, A Novel Pangenotypic Class II
Hepatitis B Virus Core Inhibitor: Preliminary Results of a 28-Day
Phase 1b Study in Nuc-Suppressed CHB Patients” Publication
Number: 822 Session Title: Hepatitis B: Therapeutics:
New Agents Presenter: Jordan J. Feld, MD, MPH, Toronto
Centre for Liver Disease, University Health Network, Toronto,
Canada
Poster Title: “EDP-514, A Potent Pangenotypic Class II
Hepatitis B Virus Core Inhibitor, Demonstrates Significant HBV DNA
and HBV RNA Reductions in a Phase 1b Study in Viremic, Chronic
Hepatitis B Infected Patients” Publication Number: 823
Session Title: Hepatitis B: Therapeutics: New Agents
Presenter: Man Fung Yuen, MBBS, MD, PhD, DSc, Department of
Medicine, Queen Mary Hospital, The University of Hong Kong, Hong
Kong
Further information about The Liver Meeting® 2021, hosted by
AASLD, can be found at: https://www.aasld.org/the-liver-meeting
.
About Enanta
Enanta is using its robust, chemistry-driven approach and drug
discovery capabilities to become a leader in the discovery and
development of small molecule drugs for the treatment of viral
infections and liver diseases. Enanta’s research and development
efforts have produced clinical candidates for the following disease
targets: respiratory syncytial virus (RSV), hepatitis B virus
(HBV), SARS-CoV-2 (COVID-19) and non-alcoholic steatohepatitis
(NASH). Enanta is also conducting research in human metapneumovirus
(hMPV).
Enanta’s research and development activities are funded by
royalties from hepatitis C virus (HCV) products developed under its
collaboration with AbbVie. Glecaprevir, a protease inhibitor
discovered by Enanta, is sold by AbbVie in numerous countries as
part of its leading treatment for chronic HCV infection under the
tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.)
(glecaprevir/pibrentasvir). Please visit www.enanta.com for more
information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211001005120/en/
Investor Contact Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Sep 2023 to Sep 2024